FDA grants Teva generic Pravachol marketing approval
Just days after Bristol-Myers Squibb’s patent for its cholesterol-lowering blockbuster Pravachol (pravastatin sodium tablets) expired on April 20, the FDA announced its approval of Teva Pharmaceuticals’ generic version of the drug.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.